William Blair Investment Management LLC Lowers Stake in Cellebrite DI Ltd. $CLBT

Key Points

• William Blair Investment Management LLC reduced its stake in Cellebrite DI Ltd. by 18.0%, now holding 552,546 shares valued at approximately $8.84 million.
• Cellebrite DI reported an earnings per share (EPS) of $0.12 for the last quarter, exceeding analysts' expectations of $0.11, alongside a revenue increase of 18.4% year-over-year.
• Despite recent upgrades from several analysts, Cellebrite DI has a consensus rating of "Moderate Buy" with a target price of $21.75.

William Blair Investment Management LLC reduced its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 18.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 552,546 shares of the company's stock after selling 121,105 shares during the quarter. William Blair Investment Management LLC owned 0.23% of Cellebrite DI worth $8,841,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Huntleigh Advisors Inc. boosted its stake in shares of Cellebrite DI by 3.9% during the 2nd quarter. Huntleigh Advisors Inc. now owns 48,950 shares of the company's stock worth $783,000 after acquiring an additional 1,821 shares in the last quarter. Nordea Investment Management AB raised its position in shares of Cellebrite DI by 2.1% during the 2nd quarter. Nordea Investment Management AB now owns 174,734 shares of the company's stock worth $2,766,000 after purchasing an additional 3,644 shares during the last quarter. TD Asset Management Inc raised its position in shares of Cellebrite DI by 99.6% during the 2nd quarter. TD Asset Management Inc now owns 212,236 shares of the company's stock worth $3,396,000 after purchasing an additional 105,930 shares during the last quarter. Meritage Portfolio Management raised its position in shares of Cellebrite DI by 2.8% during the 2nd quarter. Meritage Portfolio Management now owns 62,276 shares of the company's stock worth $996,000 after purchasing an additional 1,717 shares during the last quarter. Finally, Blue Trust Inc. raised its position in shares of Cellebrite DI by 7.2% during the 2nd quarter. Blue Trust Inc. now owns 22,223 shares of the company's stock worth $356,000 after purchasing an additional 1,497 shares during the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Trading Down 0.7%

CLBT stock opened at $18.05 on Tuesday. The company has a market cap of $4.32 billion, a price-to-earnings ratio of -23.75, a PEG ratio of 3.30 and a beta of 1.29. Cellebrite DI Ltd. has a 12 month low of $13.10 and a 12 month high of $26.30. The firm has a 50-day moving average of $17.32 and a two-hundred day moving average of $16.91.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported $0.12 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.01. The company had revenue of $113.28 million during the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. Cellebrite DI's quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on CLBT. Wall Street Zen upgraded shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research report on Friday, September 26th. Lake Street Capital reduced their price target on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research report on Friday, August 15th. JPMorgan Chase & Co. upped their price target on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 24th. Weiss Ratings restated a "sell (d+)" rating on shares of Cellebrite DI in a research report on Wednesday, October 8th. Finally, Needham & Company LLC reduced their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Cellebrite DI has a consensus rating of "Moderate Buy" and a consensus target price of $21.75.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.